Abstract:Background: Oncological treatment of breast cancer may be associated with adverse effects on myocardial function. Objectives: The objective of this study was to compare the influence of three oncological treatment methods of intervention on the echocardiographic (ECHO) parameters of left ventricular function. Materials and Methods: One hundred and fifty-five women with breast cancer were divided into three groups depending on the type of therapy used: group I (AC)—anthracyclines; group II (AC + TZ)—anthracyclines + trastuzumab; and group III (RTls+)—anthracyclines with or without trastuzumab + left-sided radiotherapy. Prospective ECHO examinations were performed at baseline and every 3 months, up to 12 months from the start of the therapy. Patients with a history of chemotherapy or who were diagnosed with heart disease were not included in the study. Results: Out of 155 patients, 3 died due to cancer as the primary cause, and 12 withdrew their consent for further observation. Baseline systolic and diastolic ECHO parameters did not differ between the analyzed groups. Cardiotoxicity, according to the LVEF criteria, occurred during follow-up in 20 patients (14.3%), irrespective of the treatment method used. Diastolic echocardiographic parameters did not change significantly after 12 months in each group, except for the left atrial volume index (LAVi), which was significantly higher in the AC + TZ compared to the values in the RTls+ group. Conclusions: All three oncologic therapeutic modalities in women with breast cancer showed no significant differences in relation to the incidence of echocardiographic cardiotoxicity criterion; however, transient systolic decrease in LVEF was most frequently observed in the AC + TZ therapeutic regimen. Left-sided radiotherapy was not associated with excess left ventricular systolic and diastolic dysfunction during a 12-month follow-up period. The predictors of negative changes in diastolic parameters included age and combined anthracycline and trastuzumab therapy.

What problem does this paper attempt to address?

The paper primarily explores the impact of three different breast cancer treatment regimens on left ventricular function. The study, through a multi-center prospective cohort design, evaluated the changes in cardiac ultrasound parameters, particularly left ventricular function, in 155 female breast cancer patients after receiving different treatments. The patients were divided into three groups: - The first group (AC group) received anthracycline chemotherapy; - The second group (AC + TZ group) received anthracycline chemotherapy plus trastuzumab treatment; - The third group (RTls+ group) received anthracycline chemotherapy, with some patients also receiving trastuzumab treatment and left-sided radiation therapy. The main objective of the study was to compare the effects of these three treatment modalities on left ventricular ultrasound parameters, particularly changes in left ventricular systolic and diastolic function. ### Findings - In all three groups, left ventricular ejection fraction (LVEF), as a standard for cardiotoxicity, decreased in 14.3% of patients, but there was no significant difference between the groups. - In patients receiving AC + TZ treatment, a temporary decrease in LVEF was most common, with an incidence of 22%. - Left-sided radiation therapy did not lead to a significant increase in left ventricular systolic or diastolic dysfunction during the 12-month follow-up period. - Age and combined anthracycline plus trastuzumab treatment were identified as independent predictors of worsening left atrial volume index (LAVi). ### Conclusion The study results indicate that there is no significant difference in the incidence of left ventricular ultrasound cardiotoxicity standards among the three breast cancer treatment regimens; however, a temporary decrease in left ventricular ejection fraction was observed in patients receiving AC + TZ treatment. Additionally, left-sided radiation therapy was not associated with an excessive occurrence of left ventricular systolic and diastolic dysfunction during the 12-month follow-up period. Age and combined anthracycline plus trastuzumab treatment are predictors of worsening left ventricular diastolic parameters.

The ONCO-ECHO Multicenter Study